TMCnet News
Cyclerion Therapeutics to Discuss CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease FoundationCompany to discuss positive topline and additional clinical data for CY6463 in MELAS patients Mitochondrial disease clinician-researcher, Amel Karaa, M.D., to discuss the potential future impact on patients Webcast scheduled for Tuesday, June 28th from 8 – 9 a.m. EDT CAMBRIDGE, Mass., June 22, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, will participate in a webinar hosted by the United Mitochondrial Disease Foundation (UMDF) on Tuesday, June 28th at 8 a.m. EDT with a live Q&A. The Company will provide an update on positive topline clinical data from the Phase 2a study of CY6463, a first-in-class CNS-penetrant sGC stimulator, in patients with Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS). For more information about the webinar, please visit the resources page of the UMDF website. “UMDF welcomes every opportunity to lift up the voices of MELAS patients and their loved ones, researchers and medical experts who know the most about this debilitating mitochondrial disease, which severely impacts multiple organs, including the CNS,” said Brian Harman, President and Chief Executive Officer of UMDF. “We are encouraged by these early CY6463 study data and look forward to discussing study findings and their potential impact for people living with MELAS.” Mitochondrial disease clinician-researcher and investigator in the MELAS study, Amel Karaa, M.D., Assistant Professor and Director of the Mitochondrial Disease Program and Lysosomal Disorders Program at Harvard Medical School and Massachusetts General Hospital, and 2013 UMDF fellow, will discuss the implications and potential future impact of these data on patients with MELAS. Dr. Karaa is a Board-certified medical geneticist who has dedicated her professional life to treating patients with complex medical conditions and established a specialized program evaluating hundreds of national and international patients with mitochondrial and lysosomal disorders. “These highly encouraging data provide additional support for the therapeutic potential of CY6463 in MELAS,” said Peter Hecht, Ph.D., Chief Executive Officer of Cyclerion. “We are excited to learn more about the potential impact of CY6463 in patients who are in desperate need of new therapeutic options.” Webinar Information About C6463 CY6463 is the first CNS-penetrant sGC stimulator to be developed as a symptomatic and potentially disease-modifying therapy for serious CNS diseases. The nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) signaling pathway is a fundamental mechanism that precisely controls key aspects of physiology throughout the body. In the CNS, the NO-sGC-cGMP pathway regulates diverse and critical biological functions including neuronal function, neuroinflammation, cellular bioenergetics, and vascular dynamics. Although it has been successfully targeted with several drugs in the periphery, this mechanism has yet to be fully leveraged therapeutically in the CNS, where impaired NO-sGC-cGMP signaling is believed to play an important role in the pathogenesis of many neurodegenerative and neuropsychiatric diseases and other disorders associated with cognitive impairment. As an sGC stimulator, CY6463 acts as a positive allosteric modulator to sensitize the sGC enzyme to NO, increase the production of cGMP, and thereby amplify endogenous NO signaling. By compensating for deficient NO-sGC-cGMP signaling, CY6463 and other sGC stimulators may have broad therapeutic potential as a treatment to improve cognition and function in people with serious CNS diseases. About the Study of CY6463 in MELAS The Phase 2a study was an open-label, single-arm study of oral, once-daily CY6463 in eight adults with MELAS. The primary objective of the study was to assess the safety and tolerability of a 15 milligram, once-daily, oral dose of CY6463 over 29 days. The secondary objectives included pharmacokinetics and exploratory pharmacodynamic effects, with the goal of identifying which biomarkers to carry forward into additional studies. About MELAS Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) is one of the most complex orphan diseases affecting multiple organ systems, including the CNS, with different degrees of severity, and no approved therapies. MELAS is caused by some of the most common mitochondrial DNA mutations affecting the mitochondrial tRNA, and results in large clusters of familial cases of primary mitochondrial diseases (PMD). It is estimated that about 1 in 4,300 individuals has a mitochondrial disease, and ~80% of individuals with mitochondrial disease have CNS symptoms. The unmet need in MELAS is immense, symptoms can affect virtually any organ and cause intense fatigue, muscle weakness, and pain in addition to neurological manifestations. Life expectancy is estimated at ~17 years from onset of CNS symptoms. The disease impedes the individual’s ability to live independently, leads to social isolation, and overall reduced quality of life. About Cyclerion Therapeutics For more information about Cyclerion, please visit https://www.cyclerion.com/ and follow us on Twitter (@Cyclerion) and LinkedIn (www.linkedin.com/company/cyclerion). Forward Looking Statement Investors Media |